Aflibercept: Newly approved for the treatment of macular edema following central retinal vein occlusion;Aflibercept: Recientemente aprobado para el tratamiento de edema macular seguido de oclusión de la vena central de la retina

Annals of Pharmacotherapy

Volumn 47, Issue 6, 2013, Pages 819-827

  Evoy, Kirk E ^a   Abel, Steven R ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; DEXAMETHASONE; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN INHIBITOR;

ARTICLE; BEST CORRECTED VISUAL ACUITY; BINDING AFFINITY; CATARACT; CENTRAL RETINA VEIN OCCLUSION; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; CORNEA EROSION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; EYE PAIN; FALLING; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INJECTION SITE PAIN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LACRIMATION; MEDLINE; PNEUMONIA; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOEMBOLISM; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY DETACHMENT; VITREOUS FLOATERS;

ANIMALS; DRUG APPROVAL; HUMANS; MACULAR EDEMA; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINAL VEIN OCCLUSION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84878498006     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R705     Document Type: Article

References (30)

1. Boyer D, Heier J, Brown DM, et al. Vascular endothelial growth factor trap-eye for macular edema secondary to central retinal vein occlusion six-month results of the phase 3 COPERNICUS study. Ophthalmology 2012;119:1024-1032.
2. Campochiaro PA. Anti-vascular endothelial growth factor treatment for retinal vein occlusions. Ophthalmologica 2012;227(suppl 1):30-35.
3. Ehlers JP, Fekrat S. Retinal vein occlusion: beyond the acute event. Surv Ophthalmol 2011;56:281-296.
4. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134-1146.
5. Browning DJ, Kaiser PK, Rosenfeld PJ, et al. Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol 2012;154:222-226.
6. Chong V. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors. Ophthalmologica 2012;227(suppl 1):2-10.
7. Csaky K, Do DV. Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. Am J Ophthalmol 2009;148:647-656.
8. Package insert. Eylea (aflibercept). Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; September 2012.
9. Heier JS, Boyer D, Nguyen QD, et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology 2011;118:1098-1106.
10. Regeneron and Bayer report positive results for VEGF Trap-Eye in second phase 3 study in central retinal vein occlusion. Tarrytown, NY and Berlin: Regeneron Pharmaceuticals, Inc., and Bayer Health Care, April 27, 2011.
11. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1124-1133.
12. Clinicaltrials.gov. Ophthalmic Consultants of Boston. Impact of intravit-real aflibercept injections on capillary non-perfusion (ANDROID). Clini-caltrial.gov identifier: NCT01724554. http://clinicaltrials.gov/ct2/show/NCT01724554?term=AFLIBERCEPT&cond=CENTRAL+RETINAL+VENOUS+OCCLUSION&rank=1 (accessed 2013 Jan 25).
13. Do VD, Nguyen QD, Shah SM, et al. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor trap-eye in patients with diabetic macular oedema. Br J Ophthalmol 2009;93:144-149.
14. Do DV, Schmidt-Erfurth U, Gonzalez VH, et al. The DA VINCI study: phase 2 primary results of VEGF trap-eye in patients with diabetic macu-lar edema. Ophthalmology 2011;118:1819-1826.
15. Nguyen QD, Campochiaro PA, Shah SM, et al. Evaluation of very high-and very low-dose intravitreal aflibercept in patients with neovascular age-related macular degeneration. J Ocul Pharmacol Ther 2012;6:581-588.
16. Nguyen QD, Shah SM, Browning DJ, et al. A phase 1 study of intravitre-al vascular endothelial growth factor trap-eye in patients with neovascu-lar age-related macular degeneration. Ophthalmology 2009;116:2141-2148.
17. Two year results of phase 3 studies with EYLEA (aflibercept) injection in wet AMD shows sustained improvement in visual acuity. Tarrytown, NY and Berlin: Regeneron Pharmaceuticals, Inc., and Bayer Health Care; December 5, 2011.
18. Boyer DS, Heier JS, Brown DM, et al. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009;116:1731-1739.
19. Regillo CD, Brown DM, Abraham P, et al. PIER Study Group. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-248.
20. Brown DM, Heier JS, Clark WL, Boyer DS, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 2013;155:429-437.
21. Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions long-term follow-up in the HORIZON trial. Ophthalmology 2012;119:802-809.
22. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2012; 119:1388-1398.
23. Red book online. Thomson Reuters. www.RedBook.com (accessed 2012 Oct 16).
24. Ip MS, Scott, IU, VanVeldhuisen PC, et al. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravit-real triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009;127:1101-1114.
25. McAllister IL, Gillies ME, Smithies LA, et al. The central retinal vein bypass study: a trial of laser-induced chorioretinal venous anastomosis for central retinal vein occlusion. Ophthalmology 2010;117:954-965.
26. Central Vein Occlusion Study Group. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. Ophthalmology 1995; 102:1434-1444.
27. Central Vein Occlusion Study Group. Evaluation of grid pattern photoco-agulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology 1995;102:1425-1433.
28. Heier JS. Intravitreal aflibercept for AMD: 2-year results. Retina Today March 2012:49-51.
29. Epstein DL, Algvere P V, von Wendt G, et al. Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology 2012;119:2587-2591.
30. Clinicaltrials.gov. Barnes Retina Institute. Bevacizumab versus ranibizumab in treatment of macular edema from vein occlusion (CRAVE). Clinical-trial.gov identifier: NCT01428388. http://clinicaltrials.gov/ct2/show/NCT01428388 (accessed 2012 Dec 22).